Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches
- 31 December 2008
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 32 (6), 505-510
- https://doi.org/10.1016/j.ijantimicag.2008.05.019
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infectionsClinics In Laboratory Medicine, 2004
- Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human TrialsAnnals of Pharmacotherapy, 2003
- New pharmacodynamic parameters for antimicrobial agentsInternational Journal of Antimicrobial Agents, 2000
- Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in Pseudomonas aeruginosaInfection Control & Hospital Epidemiology, 2000
- Achieving an Optimal Outcome in the Treatment of InfectionsClinical Pharmacokinetics, 1999
- Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired InfectionAntimicrobial Agents and Chemotherapy, 1998
- Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during TherapyAntimicrobial Agents and Chemotherapy, 1998
- Pharmacodynamics of LevofloxacinJAMA, 1998
- The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to OutcomeClinical Pharmacokinetics, 1995
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993